FAK / ALK / ROS1

Class

Multi-targeted tyrosine kinase inhibitor (FAK inhibitor and third-generation ALK/ROS1 TKI)

Pathway

Inhibits phosphorylation of FAK, ALK and ROS1 and their downstream signaling, active against tumors resistant to second-generation ALK inhibitors

FAK (focal adhesion kinase) is a non-receptor tyrosine kinase that transmits signals from cell-surface adhesion receptors called integrins, and it also intersects with growth-factor signaling to support cell survival, migration and invasion. ALK and ROS1 are receptor tyrosine kinases that, when altered by chromosomal rearrangements, become fused, constitutively active oncogenic drivers in subsets of cancers, most notably non-small cell lung cancer. Inhibiting ALK or ROS1 blocks the aberrant proliferative and survival signaling those fusions generate. Over time, however, tumors can develop resistance to ALK/ROS1 inhibitors, either through mutations in the kinase domain that impair drug binding or through activation of alternative survival pathways, such as FAK-integrin signaling, that bypass the blocked kinase. An agent designed to inhibit FAK together with ALK and ROS1 aims to suppress both the original oncogenic driver and this adaptive escape route within a single molecule, potentially maintaining tumor control after disease has progressed on earlier ALK-targeted therapies. This combined mechanism is broadly relevant to cancers driven by ALK or ROS1 fusions, and more generally to tumor biology in which FAK-mediated adhesion signaling contributes to invasive or drug-tolerant behavior.